David W Pascual

David W Pascual,

Associate Dean For Research And Graduate Studies; Professor

Department: Department of Infectious Diseases & Immunology
Business Phone: (352) 294-4104
Business Email: pascuald@ufl.edu

Research Profile

The focus of my laboratory is to understand the basic tenets of mucosal immunology and their application to improve targeted mucosal vaccine delivery. Attenuated Salmonella vectors, adept at delivering vaccines to the Peyer’s patches, elicit T helper (Th) 1 cell (IFN-γ-dependent) immune responses to resolve its infection. However, our studies show we can obtain elevated Th2 cell (IL-4- and IL-13-dependent) immune responses, followed by a delayed onset of Th1 cells to colonization factor antigen I (CFA/I), from human enterotoxigenic Escherichia coli (ETEC). Subsequent studies reveal that proinflammatory cytokine production are abated, suggesting this acts as an anti-inflammatory vaccine. Current studies are evaluating the efficacy of this vaccine against autoimmune diseases such as experimental autoimmune encephalomyelitis (EAE) and collagen-induced arthritis. Our recent findings show this vaccine induces regulatory T (Treg) cells, but the type of regulatory cell induced is disease-dependent: CD25+ Treg (EAE) and CD39+ Tregcells (arthritis). We are currently investigating how Salmonella-CFA/I stimulates the production of these Treg cells, and we are determining the involved dendritic cells that sustain these responses. Recent studies are focused on using the recombinant CFA/I fimbriae, since these were found to be as effective as the live vaccine in reducing arthritis, and on determining the underlying mechanisms for conferring protection against autoimmune insult.

Effective treatments for multiple sclerosis (MS) are problematic due to its unknown etiology. Current work has adapted the rodent EAE model to test whether our tolerogen vaccine delivery platform, the reovirus adhesin, protein sigma 1 (pσ1), can improve mucosal auto-antigen uptake. We have shown a single low-dose of pσ1-based vaccines induces tolerance and prevents or treats autoimmunity when applied mucosally. Amazingly, this new therapeutic can abate MS-like disease within 24 hrs, stimulating an array of regulatory cells to intervene in the central nervous system (CNS). This pσ1-mediated tolerance is, in part, IL-10-dependent via Treg cells. In addition, regulatory elements with the IL-4- and IL-28-producing CD25- CD4+ T cells have also been found. Further work will determine the mechanisms used by pσ1 and will help us to understand the involved dendritic cell subset(s) that stimulates regulatory T cells. Ultimately, these studies will determine the feasibility of using a pσ1-based single-dose delivery system to prevent and/or treat autoimmune diseases.

Members of Category B agents, Brucella species, are highly infectious Gram-negative bacteria that are a global health threat to both humans and livestock. Brucellosis is naturally transmitted via ingestion of unpasteurized dairy products, causing mostly a systemic disease manifesting with flu-like systems, which, despite antibiotic treatment, can cause a recurring sequelae evident as undulant fever and arthritis. Brucellae survival within the host is linked to its ability to resist intracellular recognition, thus, allowing them to sequester in various tissues. Vaccines that can recapitulate aspects of Brucella infection should prove effective to resolve such infections. Yet, to date, there are no effective vaccines for humans and inadequate vaccines for livestock. It is known protection is cell-mediated immunity-dependent and particularly involves TNF-α and IFN-γ. In this regard, we have recently developed live vaccine prototypes that can confer complete protection in some animals with no detectable brucellae. When given orally, these vaccines confer >80% protection against nasal B. melitensis infection, and of these, no brucellae (>4-5 log reduction in tissue colonization) could be detected in host tissues. Given the potency of these vaccine formulations, we are uniquely poised to test the efficacy of these vaccines against parenteral, oral, and pulmonary Brucella challenges.

Publications

2021
Antigen-encapsulating host extracellular vesicles derived from Salmonella-infected cells stimulate pathogen-specific Th1-type responses in vivo.
PLoS pathogens. 17(5) [DOI] 10.1371/journal.ppat.1009465. [PMID] 33956909.
2021
Mucosal Vaccination Primes NK Cell-Dependent Development of CD8+ T Cells Against Pulmonary Brucella Infection.
Frontiers in immunology. 12 [DOI] 10.3389/fimmu.2021.697953. [PMID] 34305935.
2021
Oral probiotic promotes indoleamine 2,3-dioxygenase- and TGF-β-Producing plasmacytoid dendritic cells to initiate protection against type 1 diabetes.
Immunology letters. 239:12-19 [DOI] 10.1016/j.imlet.2021.07.009. [PMID] 34333043.
2021
Stimulation of regulatory T cells with Lactococcus lactis expressing enterotoxigenic E. coli colonization factor antigen 1 retains salivary flow in a genetic model of Sjögren’s syndrome.
Arthritis research & therapy. 23(1) [DOI] 10.1186/s13075-021-02475-1. [PMID] 33823920.
2020
Nasal vaccination of β7 integrin-deficient mice retains elevated IgA immunity.
Immunology and cell biology. 98(8):667-681 [DOI] 10.1111/imcb.12364. [PMID] 32479679.
2020
Oral therapy with colonization factor antigen I prevents development of type 1 diabetes in Non-obese Diabetic mice.
Scientific reports. 10(1) [DOI] 10.1038/s41598-020-62881-4. [PMID] 32273533.
2020
Targeting resident memory T cell immunity culminates in pulmonary and systemic protection against Brucella infection.
PLoS pathogens. 16(1) [DOI] 10.1371/journal.ppat.1008176. [PMID] 31951645.
2019
Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.
Journal of virology. 93(14) [DOI] 10.1128/JVI.00475-19. [PMID] 31068425.
2018
Alternative strategies for vaccination to brucellosis.
Microbes and infection. 20(9-10):599-605 [DOI] 10.1016/j.micinf.2017.12.006. [PMID] 29287984.
2018
Delivery of IL-35 by Lactococcus lactis Ameliorates Collagen-Induced Arthritis in Mice.
Frontiers in immunology. 9 [DOI] 10.3389/fimmu.2018.02691. [PMID] 30515168.
2018
IL-35 (Interleukin-35) Suppresses Endothelial Cell Activation by Inhibiting Mitochondrial Reactive Oxygen Species-Mediated Site-Specific Acetylation of H3K14 (Histone 3 Lysine 14).
Arteriosclerosis, thrombosis, and vascular biology. 38(3):599-609 [DOI] 10.1161/ATVBAHA.117.310626. [PMID] 29371247.
2018
VirB10 vaccination for protection against Anaplasma phagocytophilum.
BMC microbiology. 18(1) [DOI] 10.1186/s12866-018-1346-x. [PMID] 30563470.
2016
Brucellosis vaccines for livestock.
Veterinary immunology and immunopathology. 181:51-58 [DOI] 10.1016/j.vetimm.2016.03.011. [PMID] 27032465.
2016
Development of an Avirulent Salmonella Surrogate for Modeling Pathogen Behavior in Pre- and Postharvest Environments.
Applied and environmental microbiology. 82(14):4100-4111 [DOI] 10.1128/AEM.00898-16. [PMID] 27129962.
2016
Nasal vaccination stimulates CD8(+) T cells for potent protection against mucosal Brucella melitensis challenge.
Immunology and cell biology. 94(5):496-508 [DOI] 10.1038/icb.2016.5. [PMID] 26752510.
2016
Regulatory T Cell Dysfunction Acquiesces to BTLA+ Regulatory B Cells Subsequent to Oral Intervention in Experimental Autoimmune Encephalomyelitis.
Journal of immunology (Baltimore, Md. : 1950). 196(12):5036-46 [DOI] 10.4049/jimmunol.1501973. [PMID] 27194787.
2016
Vaccination with a ΔnorD ΔznuA Brucella abortus mutant confers potent protection against virulent challenge.
Vaccine. 34(44):5290-5297 [DOI] 10.1016/j.vaccine.2016.09.004. [PMID] 27639282.
2015
Interleukin-35 Inhibits Endothelial Cell Activation by Suppressing MAPK-AP-1 Pathway.
The Journal of biological chemistry. 290(31):19307-18 [DOI] 10.1074/jbc.M115.663286. [PMID] 26085094.
2015
Isolation of oxalotrophic bacteria associated with Varroa destructor mites.
Letters in applied microbiology. 61(5):411-7 [DOI] 10.1111/lam.12486. [PMID] 26302038.
2015
Milk-based nutraceutical for treating autoimmune arthritis via the stimulation of IL-10- and TGF-β-producing CD39+ regulatory T cells.
PloS one. 10(1) [DOI] 10.1371/journal.pone.0117825. [PMID] 25629976.
2014
Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27.
Journal of immunology (Baltimore, Md. : 1950). 192(2):804-16 [DOI] 10.4049/jimmunol.1302018. [PMID] 24337375.
2014
Paratransgenesis feasibility in the honeybee (Apis mellifera) using Fructobacillus fructosus commensal.
Journal of applied microbiology. 117(6):1572-84 [DOI] 10.1111/jam.12650. [PMID] 25211052.
2014
Regulatory T-cell vaccination independent of auto-antigen.
Experimental & molecular medicine. 46 [DOI] 10.1038/emm.2014.4. [PMID] 24626168.
2013
A polymer/oil based nanovaccine as a single-dose immunization approach.
PloS one. 8(4) [DOI] 10.1371/journal.pone.0062500. [PMID] 23614052.
2013
Anti-Inflammatory Cytokine Interleukin-35 Inhibits Lipopolysaccharide-Induced Vascular Inflammation
Circulation. 128(22, S)
2013
Attenuating gene expression (AGE) for vaccine development.
Virulence. 4(5):384-90 [DOI] 10.4161/viru.24886. [PMID] 23652809.
2013
E. Coli Fimbriae Serve as An Il-35 Agonist Stimulating Indoleamine 2,3 Dioxygenase for Protection Against Collagen-Induced Arthritis
Journal of Immunology. 190
2013
Immunomodulatory activity of polysaccharides isolated from Clerodendrum splendens: beneficial effects in experimental autoimmune encephalomyelitis.
BMC complementary and alternative medicine. 13 [DOI] 10.1186/1472-6882-13-149. [PMID] 23806004.
2013
Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain.
Infection and immunity. 81(9):3099-105 [DOI] 10.1128/IAI.00203-13. [PMID] 23774604.
2013
Oral Salmonella Expressing Colonization Factor Antigen I Stimulates the Rapid Induction of Galectin-1 On Induced Treg Cells
Journal of Immunology. 190
2013
Progress in Brucella vaccine development.
Frontiers in biology. 8(1):60-77 [PMID] 23730309.
View on: PubMed
2012
18β-glycyrrhetinic acid delivered orally induces isolated lymphoid follicle maturation at the intestinal mucosa and attenuates rotavirus shedding.
PloS one. 7(11) [DOI] 10.1371/journal.pone.0049491. [PMID] 23152913.
2012
Bystander-mediated stimulation of proteolipid protein-specific regulatory T (Treg) cells confers protection against experimental autoimmune encephalomyelitis (EAE) via TGF-β.
Journal of neuroimmunology. 245(1-2):39-47 [DOI] 10.1016/j.jneuroim.2012.02.003. [PMID] 22418032.
2012
Expression of Escherichia coli virulence usher protein attenuates wild-type Salmonella.
Virulence. 3(1):29-42 [DOI] 10.4161/viru.3.1.18447. [PMID] 22286706.
2012
Flagella overexpression attenuates Salmonella pathogenesis.
PloS one. 7(10) [DOI] 10.1371/journal.pone.0046828. [PMID] 23056473.
2012
Identification and characterization of a novel class of c-Jun N-terminal kinase inhibitors.
Molecular pharmacology. 81(6):832-45 [DOI] 10.1124/mol.111.077446. [PMID] 22434859.
2012
IFN-γ-deficient mice develop IL-1-dependent cutaneous and musculoskeletal inflammation during experimental brucellosis.
Journal of leukocyte biology. 92(2):375-87 [DOI] 10.1189/jlb.1211626. [PMID] 22636321.
2012
Loss of sialic acid binding domain redirects protein σ1 to enhance M cell-directed vaccination.
PloS one. 7(4) [DOI] 10.1371/journal.pone.0036182. [PMID] 22558374.
2012
M cell-targeted mucosal vaccine strategies.
Current topics in microbiology and immunology. 354:39-52 [DOI] 10.1007/82_2011_134. [PMID] 21688209.
2012
Nasal Acai polysaccharides potentiate innate immunity to protect against pulmonary Francisella tularensis and Burkholderia pseudomallei Infections.
PLoS pathogens. 8(3) [DOI] 10.1371/journal.ppat.1002587. [PMID] 22438809.
2012
Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.
International immunology. 24(2):117-28 [DOI] 10.1093/intimm/dxr106. [PMID] 22207133.
2011
Active immunization using a single dose immunotherapeutic abates established EAE via IL-10 and regulatory T cells.
European journal of immunology. 41(2):313-23 [DOI] 10.1002/eji.201041104. [PMID] 21268002.
2011
Apple polyphenols require T cells to ameliorate dextran sulfate sodium-induced colitis and dampen proinflammatory cytokine expression.
Journal of leukocyte biology. 90(6):1043-54 [DOI] 10.1189/jlb.0311168. [PMID] 21693591.
2011
DNA vaccination of bison to brucellar antigens elicits elevated antibody and IFN-γ responses.
Journal of wildlife diseases. 47(3):501-10 [PMID] 21719815.
View on: PubMed
2011
Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.
PloS one. 6(1) [DOI] 10.1371/journal.pone.0016532. [PMID] 21304600.
2011
Murine and bovine γδ T cells enhance innate immunity against Brucella abortus infections.
PloS one. 6(7) [DOI] 10.1371/journal.pone.0021978. [PMID] 21765931.
2011
Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses.
Infection and immunity. 79(10):4165-74 [DOI] 10.1128/IAI.05080-11. [PMID] 21768283.
2011
Segregated regulatory CD39+CD4+ T cell function: TGF-β-producing Foxp3- and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis.
Journal of immunology (Baltimore, Md. : 1950). 187(9):4654-66 [DOI] 10.4049/jimmunol.1100530. [PMID] 21967895.
2011
Serum antibodies protect against intraperitoneal challenge with enterotoxigenic Escherichia coli.
Journal of biomedicine & biotechnology. 2011 [DOI] 10.1155/2011/632396. [PMID] 22007145.
2011
Tolerogen-induced interferon-producing killer dendritic cells (IKDCs) protect against EAE.
Journal of autoimmunity. 37(4):328-41 [DOI] 10.1016/j.jaut.2011.09.005. [PMID] 22018711.
2010
A parenteral DNA vaccine protects against pneumonic plague.
Vaccine. 28(18):3219-30 [DOI] 10.1016/j.vaccine.2010.02.022. [PMID] 20197132.
2010
Adenovirus F protein as a delivery vehicle for botulinum B.
BMC immunology. 11 [DOI] 10.1186/1471-2172-11-36. [PMID] 20609248.
2010
DeltaznuADeltapurE Brucella abortus 2308 mutant as a live vaccine candidate.
Vaccine. 28(4):1069-74 [DOI] 10.1016/j.vaccine.2009.10.113. [PMID] 19914192.
2010
IL-28 supplants requirement for T(reg) cells in protein sigma1-mediated protection against murine experimental autoimmune encephalomyelitis (EAE).
PloS one. 5(1) [DOI] 10.1371/journal.pone.0008720. [PMID] 20090936.
2010
IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10.
Journal of immunology (Baltimore, Md. : 1950). 184(12):7144-53 [DOI] 10.4049/jimmunol.0902739. [PMID] 20483737.
2009
An IL-12 DNA vaccine co-expressing Yersinia pestis antigens protects against pneumonic plague.
Vaccine. 27(1):80-7 [DOI] 10.1016/j.vaccine.2008.10.021. [PMID] 18955097.
2009
Antibody selection for immobilizing living bacteria.
Analytical chemistry. 81(18):7571-8 [DOI] 10.1021/ac9014484. [PMID] 19681578.
2009
Bacteria survive multiple puncturings of their cell walls.
Langmuir : the ACS journal of surfaces and colloids. 25(8):4588-94 [DOI] 10.1021/la8033319. [PMID] 19260649.
2008
A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V fusion protein confers protection against pneumonic plague.
Infection and immunity. 76(10):4564-73 [DOI] 10.1128/IAI.00581-08. [PMID] 18694965.
2008
Efficient immobilization and patterning of live bacterial cells.
Langmuir : the ACS journal of surfaces and colloids. 24(8):4161-7 [DOI] 10.1021/la7038653. [PMID] 18321142.
2008
IL-13 production by regulatory T cells protects against experimental autoimmune encephalomyelitis independently of autoantigen.
Journal of immunology (Baltimore, Md. : 1950). 181(2):954-68 [PMID] 18606647.
View on: PubMed
2008
Low-dose tolerance is mediated by the microfold cell ligand, reovirus protein sigma1.
Journal of immunology (Baltimore, Md. : 1950). 180(8):5187-200 [PMID] 18390700.
View on: PubMed
2008
Ovalbumin-protein sigma 1 M-cell targeting facilitates oral tolerance with reduction of antigen-specific CD4+ T cells.
Gastroenterology. 135(3):917-25 [DOI] 10.1053/j.gastro.2008.05.037. [PMID] 18565333.
2008
Vaccination without autoantigen protects against collagen II-induced arthritis via immune deviation and regulatory T cells.
Journal of immunology (Baltimore, Md. : 1950). 181(4):2741-52 [PMID] 18684965.
View on: PubMed
2007
Attenuated Coxiella burnetii phase II causes a febrile response in gamma interferon knockout and Toll-like receptor 2 knockout mice and protects against reinfection.
Infection and immunity. 75(12):5845-58 [PMID] 17893129.
View on: PubMed
2007
HEPES-stabilized encapsulation of Salmonella typhimurium.
Langmuir : the ACS journal of surfaces and colloids. 23(3):1365-74 [PMID] 17241060.
View on: PubMed
2007
Mucosal lymphatic-derived gammadelta T cells respond early to experimental Salmonella enterocolitis by increasing expression of IL-2R alpha.
Cellular immunology. 246(1):8-16 [PMID] 17574223.
View on: PubMed
2007
Mucosal vaccine development for botulinum intoxication.
Expert review of vaccines. 6(1):35-45 [PMID] 17280477.
View on: PubMed
2007
Nasal immunization with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization.
Vaccine. 25(12):2261-8 [PMID] 17239499.
View on: PubMed
2007
Oral vaccination with salmonella simultaneously expressing Yersinia pestis F1 and V antigens protects against bubonic and pneumonic plague.
Journal of immunology (Baltimore, Md. : 1950). 178(2):1059-67 [PMID] 17202369.
View on: PubMed
2007
Regulatory T cell vaccination without autoantigen protects against experimental autoimmune encephalomyelitis.
Journal of immunology (Baltimore, Md. : 1950). 178(3):1791-9 [PMID] 17237429.
View on: PubMed
2006
Deletion of znuA virulence factor attenuates Brucella abortus and confers protection against wild-type challenge.
Infection and immunity. 74(7):3874-9 [PMID] 16790759.
View on: PubMed
2006
Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A.
Journal of immunology (Baltimore, Md. : 1950). 177(8):5524-32 [PMID] 17015739.
View on: PubMed
2005
A live diarrheal vaccine imprints a Th2 cell bias and acts as an anti-inflammatory vaccine.
Journal of immunology (Baltimore, Md. : 1950). 175(10):6733-40 [PMID] 16272329.
View on: PubMed
2005
A novel neurotoxoid vaccine prevents mucosal botulism.
Journal of immunology (Baltimore, Md. : 1950). 174(4):2190-5 [PMID] 15699151.
View on: PubMed
2005
Enhanced immunoglobulin A response and protection against Salmonella enterica serovar typhimurium in the absence of the substance P receptor.
Infection and immunity. 73(1):317-24 [PMID] 15618168.
View on: PubMed
2005
Expression and immunogenicity of an Escherichia coli K99 fimbriae subunit antigen in soybean.
Planta. 222(1):6-18 [PMID] 15609046.
View on: PubMed
2005
Partially assembled K99 fimbriae are required for protection.
Infection and immunity. 73(11):7274-80 [PMID] 16239523.
View on: PubMed
2005
Selection of protective epitopes for Brucella melitensis by DNA vaccination.
Infection and immunity. 73(11):7297-303 [PMID] 16239526.
View on: PubMed
2005
Transgene vaccination using Ulex europaeus agglutinin I (UEA-1) for targeted mucosal immunization against HIV-1 envelope.
Vaccine. 23(29):3836-42 [PMID] 15893622.
View on: PubMed
2004
The role of tachykinins on bacterial infections.
Frontiers in bioscience : a journal and virtual library. 9:3209-17 [PMID] 15353350.
View on: PubMed
2003
M cell DNA vaccination for CTL immunity to HIV.
Journal of immunology (Baltimore, Md. : 1950). 171(9):4717-25 [PMID] 14568947.
View on: PubMed
2003
New benzimidazole derivatives: selective and orally active 5-HT3 receptor antagonists.
European journal of pharmacology. 462(1-3):99-107 [PMID] 12591101.
View on: PubMed
2003
Segregation of mechanisms for cytotoxic T lymphocyte killing between lungs and regional lymph nodes subsequent to intratracheal delivery of adenovirus 2 vector.
Viral immunology. 16(4):525-39 [PMID] 14733739.
View on: PubMed
2002
Absence of L-selectin delays mucosal B cell responses in nonintestinal effector tissues.
Journal of immunology (Baltimore, Md. : 1950). 169(10):5649-59 [PMID] 12421944.
View on: PubMed
2002
Development of a transient CD4(+)CD8(+) T cell subset in the cervical lymph nodes following intratracheal instillation with an adenovirus vector.
Cellular immunology. 215(2):173-85 [PMID] 12202154.
View on: PubMed
2002
Fimbriated Salmonella enterica serovar typhimurium abates initial inflammatory responses by macrophages.
Infection and immunity. 70(8):4273-81 [PMID] 12117936.
View on: PubMed
2002
Mucosal addressin expression and binding-interactions with naive lymphocytes vary among the cranial, oral, and nasal-associated lymphoid tissues.
European journal of immunology. 32(11):3029-39 [PMID] 12385022.
View on: PubMed
2001
Cutting edge: dichotomy of homing receptor dependence by mucosal effector B cells: alpha(E) versus L-selectin.
Journal of immunology (Baltimore, Md. : 1950). 167(5):2441-5 [PMID] 11509580.
View on: PubMed
2001
Impaired mucosal immunity in L-selectin-deficient mice orally immunized with a Salmonella vaccine vector.
Journal of immunology (Baltimore, Md. : 1950). 167(1):407-15 [PMID] 11418677.
View on: PubMed
2001
M cell-targeted DNA vaccination.
Proceedings of the National Academy of Sciences of the United States of America. 98(16):9318-23 [PMID] 11459939.
View on: PubMed
2001
The protective role of interleukin-18 in Salmonella infection.
Current opinion in infectious diseases. 14(3):265-71 [PMID] 11964842.
View on: PubMed
2000
Gene transfer facilitated by a cellular targeting molecule, reovirus protein sigma1.
Gene therapy. 7(1):61-9 [PMID] 10680017.
View on: PubMed
1999
Expression of recombinant enterotoxigenic Escherichia coli colonization factor antigen I by Salmonella typhimurium elicits a biphasic T helper cell response.
Infection and immunity. 67(12):6249-56 [PMID] 10569734.
View on: PubMed
1999
Nasal-associated lymphoid tissue: phenotypic and functional evidence for the primary role of peripheral node addressin in naive lymphocyte adhesion to high endothelial venules in a mucosal site.
Journal of immunology (Baltimore, Md. : 1950). 163(3):1382-9 [PMID] 10415038.
View on: PubMed
1999
Role of endogenous interleukin-18 in resolving wild-type and attenuated Salmonella typhimurium infections.
Infection and immunity. 67(12):6242-8 [PMID] 10569733.
View on: PubMed
1998
Differential regulation of expression of the MHC class II molecules RT1.B and RT1.D on rat B lymphocytes: effects of interleukin-4, interleukin-13 and interferon-gamma.
Immunology. 93(1):33-40 [PMID] 9536116.
View on: PubMed
1998
Oral immunization with a Salmonella typhimurium vaccine vector expressing recombinant enterotoxigenic Escherichia coli K99 fimbriae elicits elevated antibody titers for protective immunity.
Infection and immunity. 66(11):5470-6 [PMID] 9784559.
View on: PubMed
1998
Regulation of host immune responses by modification of Salmonella virulence genes.
Nature medicine. 4(11):1247-52 [PMID] 9809547.
View on: PubMed
1998
Repeated intratracheal instillations of nonreplicating adenovirus 2 vector attenuate CTL responses and IFN-gamma production.
Journal of immunology (Baltimore, Md. : 1950). 160(9):4465-72 [PMID] 9574552.
View on: PubMed
1997
Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene.
Journal of immunology (Baltimore, Md. : 1950). 159(2):685-93 [PMID] 9218583.
View on: PubMed
1997
Expression of recombinant rat interleukin-13 (IL-13) and generation of a neutralizing rat IL-13 antiserum.
Biochemical and biophysical research communications. 235(3):529-32 [PMID] 9207190.
View on: PubMed
1997
Induction of mucosal and systemic responses against human immunodeficiency virus type 1 glycoprotein 120 in mice after oral immunization with a single dose of a Salmonella-HIV vector.
AIDS research and human retroviruses. 13(14):1187-94 [PMID] 9310285.
View on: PubMed
1997
Oral bacterial vaccine vectors for the delivery of subunit and nucleic acid vaccines to the organized lymphoid tissue of the intestine.
Behring Institute Mitteilungen. (98):143-52 [PMID] 9382735.
View on: PubMed
1997
Spontaneously hypertensive rat: cholera toxin converts suppression to immunity through a Th2 cell-IL-4 pathway.
The American journal of physiology. 273(4):R1509-18 [DOI] 10.1152/ajpregu.1997.273.4.R1509. [PMID] 9362318.
1996
Optimization of live oral Salmonella-HIV-1 vaccine vectors for the induction of HIV-specific mucosal and systemic immune responses.
Journal of biotechnology. 44(1-3):203-7 [PMID] 8717405.
View on: PubMed
1996
Recognition of neurokinin 1 receptor (NK1-R): an antibody to a peptide sequence from the third extracellular region binds to brain NK1-R.
Journal of neuroimmunology. 67(1):49-58 [PMID] 8707930.
View on: PubMed
1996
Regulation of mucosal and systemic antibody responses by T helper cell subsets, macrophages, and derived cytokines following oral immunization with live recombinant Salmonella.
Journal of immunology (Baltimore, Md. : 1950). 156(4):1504-14 [PMID] 8568254.
View on: PubMed
1996
Systematic analysis of repeated gene delivery into animal lungs with a recombinant adenovirus vector.
Human gene therapy. 7(3):319-31 [PMID] 8835219.
View on: PubMed
1995
Immune responses to novel Escherichia coli and Salmonella typhimurium vectors that express colonization factor antigen I (CFA/I) of enterotoxigenic E. coli in the absence of the CFA/I positive regulator cfaR.
Infection and immunity. 63(12):4933-8 [PMID] 7591160.
View on: PubMed
1995
Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase.
Human gene therapy. 6(7):895-903 [PMID] 7578408.
View on: PubMed
1995
Substance P promotes Peyer’s patch and splenic B cell differentiation.
Advances in experimental medicine and biology. 371A:55-9 [PMID] 8525987.
View on: PubMed
1994
The enteric nervous and immune systems: interactions for mucosal immunity and inflammation.
ImmunoMethods. 5(1):56-72 [PMID] 7531102.
View on: PubMed
1993
Nitric oxide mediates immune dysfunction in the spontaneously hypertensive rat.
Hypertension (Dallas, Tex. : 1979). 21(2):185-94 [PMID] 7679089.
View on: PubMed
1993
Phylogenetic and serological characterization of two Ugandan HIV-1 isolates.
AIDS research and human retroviruses. 9(4):351-6 [PMID] 8512751.
View on: PubMed
1992
Low temperature pepsin proteolysis. An effective procedure for mouse IgM F(ab’)2 fragment production.
Journal of immunological methods. 146(2):249-55 [PMID] 1538146.
View on: PubMed
1992
Modulation of the mRNAs encoding substance P and its receptor in rat macrophages by LPS.
Regional immunology. 4(2):105-12 [PMID] 1380279.
View on: PubMed
1992
Spontaneously hypertensive rat: lymphoid depression is age dependent and mediated via a mononuclear cell subpopulation.
The American journal of physiology. 262(1 Pt 2):R1-7 [PMID] 1733328.
View on: PubMed
1992
Substance P: a late-acting B lymphocyte differentiation cofactor.
The American journal of physiology. 262(3 Pt 1):C537-45 [PMID] 1372476.
View on: PubMed
1992
The cytokine-like action of substance P upon B cell differentiation.
Regional immunology. 4(2):100-4 [PMID] 1380278.
View on: PubMed
1991
Neuroimmune modulation of lymphocyte function–I. Substance P enhances immunoglobulin synthesis in lipopolysaccharide activated murine splenic B cell cultures.
International immunology. 3(12):1223-9 [PMID] 1723293.
View on: PubMed
1991
Substance P acts directly upon cloned B lymphoma cells to enhance IgA and IgM production.
Journal of immunology (Baltimore, Md. : 1950). 146(7):2130-6 [PMID] 1706387.
View on: PubMed
1991
The regulation of antibody responses by mini-cytokines.
Acta neurologica. 13(4):343-9 [PMID] 1723564.
View on: PubMed
1990
5′-3′ and 3′-5′ translation of the same RNA results in hydropathically similar peptides that are antigenically related.
Immunological investigations. 19(5-6):421-33 [PMID] 1705918.
View on: PubMed
1990
Interleukin-2 does not attenuate hypertension in spontaneously hypertensive rats.
Hypertension (Dallas, Tex. : 1979). 16(4):468-71 [PMID] 2210814.
View on: PubMed
1990
Modulation of IgM secretion and H chain mRNA expression in CH12.LX.C4.5F5 B cells by adrenocorticotropic hormone.
Journal of immunology (Baltimore, Md. : 1950). 145(12):4326-31 [PMID] 2175328.
View on: PubMed
1990
Substance P production by P388D1 macrophages: a possible autocrine function for this neuropeptide.
Immunology. 71(1):52-6 [PMID] 1698717.
View on: PubMed
1989
Anti-peptide antibodies recognize anti-substance P antibodies in an idiotypic fashion.
Peptide research. 2(3):207-12 [PMID] 2485208.
View on: PubMed
1989
Antipeptide antibodies that recognize a lymphocyte substance P receptor.
Journal of immunology (Baltimore, Md. : 1950). 143(11):3697-702 [PMID] 2479686.
View on: PubMed
1988
Antibodies against a peptide sequence within the HIV envelope protein crossreacts with human interleukin-2.
Immunological investigations. 17(6-7):577-86 [PMID] 2466783.
View on: PubMed
1988
Ligand binding by murine IgM antibodies: intramolecular heterogeneity exists in certain, but not all, cases.
Molecular immunology. 25(1):87-94 [PMID] 3343976.
View on: PubMed
1987
Conformational changes in the DNA of hybridoma cells from pristane treated mice.
Chemico-biological interactions. 61(3):249-63 [PMID] 3568195.
View on: PubMed
1987
Neutralizing antibody to the AIDS virus. Prevalence, clinical significance and virus strain specificity.
Antibiotics and chemotherapy. 38:151-8 [PMID] 2444154.
View on: PubMed

Grants

Feb 2021 ACTIVE
SBIR Phase II – A Novel, Immunologically Engineered Probiotic for Treating Rheumatoid Arthritis
Role: Principal Investigator
Funding: RISE THERAPEUTICS via NATL INST OF HLTH NIAID
Apr 2020 ACTIVE
Snodgrassella alvi as an attenuated live vaccine against Neisseria gonorrhoeae
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Aug 2019 – Aug 2020
Evaluation of VTC-D87 with IL-2mutein to measure Treg durability in the NOD model
Role: Principal Investigator
Funding: VIRTICI LLC
Jul 2019 ACTIVE
A Novel Probiotic for the Treatment of Sj?grens Syndrome
Role: Principal Investigator
Funding: RISE THERAPEUTICS via NATL INST OF HLTH NIDCR
Oct 2018 – Mar 2020
Evaluation of VTC-MS3 in the EAE model
Role: Principal Investigator
Funding: VIRTICI LLC
Jan 2018 – Mar 2019
Brucellosis Vaccine Prize: Phase 1
Role: Co-Investigator
Funding: GALVMED
Aug 2017 ACTIVE
Naso-oropharyngeal Brucella Infections and Mucosal Immune Protection
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Apr 2017 ACTIVE
Regulatory Cell Therapy for Sj?grens Syndrome.
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDCR
Apr 2017 – Jun 2021
OoR CTSI Institutional Matching Support
Role: Project Manager
Funding: UF DIV OF SPONSORED RES MATCHING FUNDS
Jan 2017 – May 2017
Evaluation of VTC-MS3 in the EAE model
Role: Principal Investigator
Funding: VIRTICI LLC
Aug 2016 – Jul 2018
A Novel Probiotic for the Treatment of Sjogren's Syndrome.
Role: Principal Investigator
Funding: VIRTICI LLC via NATL INST OF HLTH NIDCR
May 2016 – Apr 2017
Sony cell sorter SH800 system
Role: Principal Investigator
Funding: NATL INST OF HLTH OD
Mar 2016 – Feb 2019
Fimbriae Countermeasures for Type 1 Diabetes
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Jan 2016 ACTIVE
Mucosal Vaccines for Brucellosis
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Jan 2015 – Nov 2016
TARGETED MUCOSAL VACCINES FOR BOTULINUM
Role: Principal Investigator
Funding: UF FOUNDATION
Sep 2013 – Aug 2018
Brucellosis Vaccines for Livestock
Role: Principal Investigator
Funding: US DEPT OF AG NATL INST OF FOOD AND AG
Nov 2012 – Apr 2017
Subunit Vaccines for Brucella Pathogens.
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
Jul 2012 – Jun 2017
Mucosal vaccination to protect against HIV-1 infection at mucosal sites
Role: Principal Investigator
Funding: DUKE UNIVERSITY via NATL INST OF HLTH

Education

Doctor of Philosophy
1987 · University of Mississippi
Master of Science
1985 · University of Mississippi

Teaching Profile

Courses Taught
2018
VME7979 Advanced Research
2018
MCB7979 Advanced Research
2018
VME7980 Research for Doctoral Dissertation
2016-2017
VEM5131 Vet Molecular Biology
2017
VME6934 Topics in Veterinary Medical Sciences

Contact Details

Phones:
Business:
(352) 294-4104
Emails:
Business:
pascuald@ufl.edu